Compare OMH & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OMH | IMNN |
|---|---|---|
| Founded | 2015 | 1982 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 5.1M |
| IPO Year | 2022 | 2000 |
| Metric | OMH | IMNN |
|---|---|---|
| Price | $4.97 | $0.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | ★ 7.9M | 126.8K |
| Earning Date | 09-10-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $39.14 | N/A |
| Revenue Next Year | $145.74 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.06 | $0.50 |
| 52 Week High | $94.60 | $4.35 |
| Indicator | OMH | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 47.89 | 24.50 |
| Support Level | $1.00 | N/A |
| Resistance Level | N/A | $1.28 |
| Average True Range (ATR) | 14.69 | 0.11 |
| MACD | -0.18 | -0.02 |
| Stochastic Oscillator | 2.28 | 16.95 |
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, Digital Marketing Services, and emerging and other services. The firm operates in two segments, which are Brokerage, emerging and another related service; and Estate management services and other related services in Singapore.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.